KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Common Equity (2016 - 2025)

Travere Therapeutics' Common Equity history spans 15 years, with the latest figure at $114.8 million for Q4 2025.

  • For Q4 2025, Common Equity rose 94.37% year-over-year to $114.8 million; the TTM value through Dec 2025 reached $114.8 million, up 94.37%, while the annual FY2025 figure was $114.8 million, 94.37% up from the prior year.
  • Common Equity reached $114.8 million in Q4 2025 per TVTX's latest filing, up from $73.6 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $362.7 million in Q1 2021 to a low of -$30.5 million in Q3 2024.
  • Average Common Equity over 5 years is $148.5 million, with a median of $115.7 million recorded in 2023.
  • Peak YoY movement for Common Equity: surged 368.62% in 2023, then crashed 110.89% in 2024.
  • A 5-year view of Common Equity shows it stood at $302.1 million in 2021, then crashed by 85.82% to $42.9 million in 2022, then skyrocketed by 368.62% to $200.8 million in 2023, then tumbled by 70.58% to $59.1 million in 2024, then skyrocketed by 94.37% to $114.8 million in 2025.
  • Per Business Quant, the three most recent readings for TVTX's Common Equity are $114.8 million (Q4 2025), $73.6 million (Q3 2025), and $32.7 million (Q2 2025).